Darolutamide Shows Superior Real-World Effectiveness in Non-metastatic CRPC
The expanded DEAR-EXT study found that darolutamide delivered superior real-world outcomes compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer. Across 1,375 patients, darolutamide was associated with lower discontinuation rates, delayed metastatic progression, and improved metastasis-free survival, supporting its use as a preferred first-line ARI for high-risk nmCRPC.